Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Palmer

Showing results (1-10 of 222) with videos related to

Pageof 23
Sort By:
Kidney International. Supplement|October 16, 2004
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuriaAndrew J Palmer, Roger A Rodby
Amino Acids|December 4, 2009
The polyamine transport system as a target for anticancer drug developmentAndrew J Palmer, Heather M Wallace
BMC Health Services Research|December 30, 2017
Improving equity in health care financing in China during the progression towards Universal Health CoverageMingsheng Chen, Andrew J Palmer, Lei Si
International Journal for Equity in Health|January 22, 2016
Assessing equity in benefit distribution of government health subsidy in 2012 across East China: benefit incidence analysisMingsheng Chen, Andrew J Palmer, Lei Si
International Journal for Equity in Health|January 11, 2017
Has equity in government subsidy on healthcare improved in China? Evidence from the China's National Health Services SurveyLei Si, Mingsheng Chen, Andrew J Palmer
Primary Care Diabetes|November 13, 2010
The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the futureDaniel M D Tucker, Andrew J Palmer
Ugeskrift for Laeger|April 25, 2008
[Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark]Andrew J Palmer, Morten Lammert, Kjeld Hermansen
Pharmacoeconomics|May 31, 2002
Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in CanadaDouglas Coyle, Andrew J Palmer, Robert Tam
Health Policy (Amsterdam, Netherlands)|May 31, 2016
The new Australian after-hours general practice incentive payment mechanism: equity for rural general practice?Amanda L Neil, Mark Nelson, Andrew J Palmer
Health and Quality of Life Outcomes|January 11, 2017
Multimorbidity and health-related quality of life (HRQoL) in a nationally representative population sample: implications of count versus cluster method for defining multimorbidity on HRQoLLili Wang, Andrew J Palmer, Fiona Cocker, et al.
Pageof 23

Showing results (1-10 of 222) with videos related to

Sort By:
Pageof 23
Kidney International. Supplement|October 16, 2004
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuriaAndrew J Palmer, Roger A Rodby
Amino Acids|December 4, 2009
The polyamine transport system as a target for anticancer drug developmentAndrew J Palmer, Heather M Wallace
BMC Health Services Research|December 30, 2017
Improving equity in health care financing in China during the progression towards Universal Health CoverageMingsheng Chen, Andrew J Palmer, Lei Si
International Journal for Equity in Health|January 22, 2016
Assessing equity in benefit distribution of government health subsidy in 2012 across East China: benefit incidence analysisMingsheng Chen, Andrew J Palmer, Lei Si
International Journal for Equity in Health|January 11, 2017
Has equity in government subsidy on healthcare improved in China? Evidence from the China's National Health Services SurveyLei Si, Mingsheng Chen, Andrew J Palmer
Primary Care Diabetes|November 13, 2010
The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the futureDaniel M D Tucker, Andrew J Palmer
Ugeskrift for Laeger|April 25, 2008
[Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark]Andrew J Palmer, Morten Lammert, Kjeld Hermansen
Pharmacoeconomics|May 31, 2002
Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in CanadaDouglas Coyle, Andrew J Palmer, Robert Tam
Health Policy (Amsterdam, Netherlands)|May 31, 2016
The new Australian after-hours general practice incentive payment mechanism: equity for rural general practice?Amanda L Neil, Mark Nelson, Andrew J Palmer
Health and Quality of Life Outcomes|January 11, 2017
Multimorbidity and health-related quality of life (HRQoL) in a nationally representative population sample: implications of count versus cluster method for defining multimorbidity on HRQoLLili Wang, Andrew J Palmer, Fiona Cocker, et al.
Pageof 23